The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Rykov M.Iu.

Nauchno-issledovatel'skiĭ institut detskoĭ onkologii i gematologii Rossiĭskogo onkologicheskogo nauchnogo tsentra im. N.N. Blokhina RAMN, Moskva

Buĭdenok Iu.V.

Nauchno-issledovatel'skiĭ institut detskoĭ onkologii i gematologii Rossiĭskogo onkologicheskogo nauchnogo tsentra im. N.N. Blokhina RAMN, Moskva

The optimal venous access for the chemotherapy in children

Authors:

Rykov M.Iu., Buĭdenok Iu.V.

More about the authors

Journal: Pirogov Russian Journal of Surgery. 2012;(9): 60‑63

Read: 767 times

Download PDF (RU)
Contact the author
Table of contents

THE OPTIMAL VENOUS ACCESS FOR THE CHEMOTHERAPY IN CHILDREN
THE OPTIMAL VENOUS ACCESS FOR THE CHEMOTHERAPY IN CHILDREN

To cite this article:

Rykov MIu, Buĭdenok IuV. The optimal venous access for the chemotherapy in children. Pirogov Russian Journal of Surgery. 2012;(9):60‑63. (In Russ.)

Подписка 2025-2 (Pirogov Russian Journal of Surgery)
МСФ на ЯМ
Использование инфографики авторами научных работ
Mediasphera_Net
Close metadata
Recommended articles:
The Russian consensus on the treatment of intrahepatic cholangiocarcinoma. Piro­gov Russian Journal of Surgery. 2024;(10):7-20
Primary outcomes after major anatomical liver rese­ctions in infa­nts at the National Children’s Medi­cal Center. Piro­gov Russian Journal of Surgery. 2025;(4):86-94
Tumor models in cancer research. P.A. Herzen Journal of Onco­logy. 2024;(4):72-76
Cost of supportive cancer care in the Russian Fede­ration. Part 1. Medi­cal Technologies. Asse­ssment and Choice. 2024;(3):93-103
Asse­ssment of cyto­kine status in patients with onco­logical diseases and severe COVID-19. Russian Journal of Evidence-Based Gastroenterology. 2024;(3):60-66
Oral cavity cancer epidemiology in men and women in the Sibe­rian Fede­ral District. Russian Journal of Preventive Medi­cine. 2024;(11):46-53
Cost of supportive cancer care in the Russian Fede­ration. Part 2. Medi­cal Technologies. Asse­ssment and Choice. 2024;(4):63-73
History creates man, and man creates history. On the 125th anni­versary of the P.A. Herzen Moscow Onco­logy Research Institute. P.A. Herzen Journal of Onco­logy. 2024;(6):5-11
Use of a new tetrapeptide analgesic at the stages of anti­tumor therapy. P.A. Herzen Journal of Onco­logy. 2024;(6):23-32
Left ventricular myocardial performance index (Tei index) as an early marker of cardiotoxicity in anti­tumor therapy. Russian Cardiology Bulletin. 2024;(4-2):137-143

The optimal choice for the long-term venous access for children is a full implanted venous port systems. We own the experience of 87 port implantations to children aged from 6 months to 17 years with various oncological disease. The experience was successful in all cases but one, where the septic inflammation of the subcutaneous pocket developed.

Keywords:

oncology
chemotherapy
venous port-systems
venous acces

Authors:

Rykov M.Iu.

Nauchno-issledovatel'skiĭ institut detskoĭ onkologii i gematologii Rossiĭskogo onkologicheskogo nauchnogo tsentra im. N.N. Blokhina RAMN, Moskva

Buĭdenok Iu.V.

Nauchno-issledovatel'skiĭ institut detskoĭ onkologii i gematologii Rossiĭskogo onkologicheskogo nauchnogo tsentra im. N.N. Blokhina RAMN, Moskva

List of references:

  1. Buidenok Yu.V., Meshcheryakov A.A. Implantiruemye port-sistemy venoznogo dostupa v onkologii. Vestn intens terapii 2004; 3: 3-8.
  2. Galt'eri I., Deppe I., Siperli M., Tomson D. Kateterizatsiya podklyuchichnoi veny: ul'trazvukovoi kontrol' pozvolyaet menee opytnym vracham dobit'sya luchshikh rezul'tatov. Vestn intens terapii 2006; 4: 24-30.
  3. Egiev V.N., Shchetinin V.V., Trofimenko Yu.G. Polnost'yu implantiruemye sistemy v meditsine. M: Medpraktika-M 2004; 60.
  4. Sukhorukov V.P., Berdikyan A.S., Epshtein S.L. Punktsiya i kateterizatsiya ven. Traditsionnye i novye tekhnologii. Posobie dlya vrachei. Sankt-Peterburgskoe meditsinskoe izdatel'stvo 2001; 55.
  5. Blenkharn J.I. In vitro antibacterial activity of noxythiolin and taurolidine. J Pharm Pharmacol 1990; 42: 589-590.
  6. Browne M.K., Leslie G.B., Pfirrmann R.W. Taurolin, a new chemothera peutic agent. J Appl Bacteriol 1976; 41: 363-368.
  7. Browne M.K. Pharmacological and clinical studies with Taurolin®. In: Bruckner W.L., Pfirrman R.W.R., editors. Proceedings of the International Taurolin Symposium 1985.
  8. Calabresi P., Goulette F.A., Darnowski J.W. Taurolidine: cytotoxic and mechanistic evaluation of a novel antineoplastic agent. Cancer Res 2001; 61: 6816-6821.

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.